Advanced Cell Technology (ACTC) announces plan to make iPS cell-derived platelets: some thoughts

Advanced Cell Technology (ACT) is well into clinical trials for macular degeneration (the leading cause of blindness) using human embryonic stem cell (hESC)-based retinal pigmented epithelial cells (RPE). To date, the trials suggest the products are safe. Efficacy? We don’t know. I am cautiously hopeful, but it is frustrating to know that most clinical trials …

Advanced Cell Technology (ACTC) announces plan to make iPS cell-derived platelets: some thoughts Read More »